Catalent Makes Two Key European Appointments in Oral Dose Manufacturing
Catalent Pharma Solutions has made two key appointments at its Schorndorf, and Eberbach, Germany, facilities.
Dr Irmgard Neuper is the new General Manager at Catalent’s Schorndorf facility, which provides large-scale, complex oral solid manufacturing with integrated analytical, development, and packaging services.
Dr Neuper joins Catalent from Sandoz, with 17 years of operating and leadership experience in Technical Operations functions in Austria, the US, Germany and Brazil, where she gained significant expertise in manufacturing, from early pharmaceutical intermediates to finished dosage forms. Her most recent role at Sandoz was as Site Head at the company’s Gerlingen, Germany, facility.
Prior to this, she served in a number of roles at Sandoz, including Global Quality Project Manager; Site Head for Solid Oral Dosage forms and Liquids in Brazil; Head of Production for Frankfurt Industrial products; and Project Manager for R&D at the Geneva, US, site.
Dr Neuper has a PhD in Agricultural Sciences and a Diploma in Engineering for Food and Biotechnology, both from University for Agricultural Sciences, Vienna.
In a second announcement, Luc Burgard will become the new General Manager of Catalent’s 360,000 sq.ft. Eberbach softgel manufacturing facility.
Mr Burgard joined Catalent in October 2011 as European Operational Excellence Leader, based in Beinheim, France, before being appointed as Operations Director at the Eberbach site in April 2013. Prior to joining Catalent, he was employed by Faurecia, a global automotive technology supplier for 9 years, working in progressively senior operational roles including the Global Leader in Engineering Methodologies.
Mr Burgard holds a Bachelor’s Degree in electronics and quality from Cergy-Pontoise University, as well as an Advanced Master’s Degree in innovative design and mathematics from the Institut National des Sciences Appliquées of Strasbourg.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance